Skip to main content
Premium Trial:

Request an Annual Quote

New Rules at PhRMA to Change Industry's Image

The drug industry's main lobbying group is kicking out members that don't spend enough on developing new products.

According to new rules from the Pharmaceutical Research and Manufacturers of America that went into effect this week, in order to remain members, drug firms  will have to spend at least 10 percent of their sales on global research and development over three years. They will also need to spend at least $200 million per year on R&D.

“By putting in place new membership criteria, the board is sending a clear message that being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients,” said Joaquin Duato, PhRMA board chairman and worldwide chairman, pharmaceuticals, Johnson & Johnson, said in a statement posted on the trade group's website.

Once the new rules took effect, seven members lost their PhRMA membership because they didn't meet the new criteria, according to the Washington Examiner, while 15 other companies were dropped after the "associate" membership category was eliminated.

The rules change comes as pharma tries to rehabilitate its image as greedy profiteers of sickness and disease, spurred on by news reports of outrageous hikes — e.g. Mylan and Turing Pharmaceuticals, formerly run by the infamous Martin Shkreli — in drug prices. Even President Donald Trump, not exactly a foe of free market economics, has verbally upbraided the industry for its practices.

Drug companies have defended their prices by saying it can cost billions of dollars to develop a drug, without any guarantee of success. But detractors note that some firms have hiked the prices of some drugs after acquiring the rights to them, without performing any of the expensive R&D.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.